From the Guidelines
Mometasone furoate nasal spray is approved for use in children as young as 2 years old for allergic rhinitis symptoms. According to the clinical practice guideline: allergic rhinitis study published in 2015 1, the minimum pediatric age for the use of Mometasone nasal spray is 2 years old.
Key Points to Consider
- For children aged 2-11, the recommended dosage is one spray (50 mcg) in each nostril once daily.
- Children 12 and older can use the adult dosage of two sprays (100 mcg) in each nostril once daily.
- The study provides information on various intranasal steroids, including Mometasone furoate, and their approved ages for use, with Mometasone being approved for children as young as 2 years old 1.
Administration and Side Effects
- Before first use, prime the pump by pressing 10 times until a fine mist appears.
- For regular use, shake well before each application, insert the tip into the nostril pointing away from the septum, and spray while breathing in gently through the nose.
- Mometasone works as a corticosteroid by reducing inflammation in the nasal passages, decreasing symptoms like congestion, runny nose, and sneezing.
- Side effects may include nasal irritation, headache, or nosebleeds, as reported in the study 1.
Important Considerations for Long-Term Use
- Parents should monitor growth in children on long-term therapy, as intranasal corticosteroids may potentially affect growth velocity, though mometasone has minimal systemic absorption compared to other corticosteroids.
From the FDA Drug Label
Adults & children 12 years of age and older Children 2 to 11 years of age Children under 2 years of age ■ do not use Children age 2 to 11 An adult should supervise use Users age 12 or older
The minimum pediatric age for the use of Mometasone nasal spray is 2 years of age 2 2.
- Key points:
- Children under 2 years of age should not use the product.
- Children between 2 to 11 years of age can use the product with adult supervision.
From the Research
Minimum Pediatric Age for Mometasone Nasal Spray
- The minimum pediatric age for the use of Mometasone (m-desktop corticosteroid) nasal spray is 2 years of age, as stated in the study 3.
- However, most of the studies provided have focused on children aged 6-11 years, with some studies including children as young as 3 years old 4.
- The study 4 evaluated the efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis, and included children aged 3-11 years.
- Another study 5 assessed the safety of mometasone furoate nasal spray in pediatric subjects aged 6-17 years with bilateral nasal polyps.
Approved Age Range
- Mometasone furoate aqueous nasal spray is approved for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in patients ≥ 12 years of age, and for the treatment of SAR and PAR in children as young as 2 years of age 3.
- The approved age range may vary depending on the specific indication and dosage, as seen in the study 5 where children aged 6-11 years received a different dosage than those aged 12-17 years.
Key Findings
- The studies provided have consistently shown that mometasone furoate nasal spray is safe and effective in children with allergic rhinitis, with negligible systemic activity and no evidence of suppression of the hypothalamic-pituitary-adrenal axis 3, 6, 7, 4.
- The most appropriate therapeutic dosage of mometasone furoate nasal spray in children with SAR is 100 microgram once daily, as demonstrated in the study 6.